Cidara Therapeutics Inc
CDTX220.800USD
-0.060-0.03%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
6.48BMarket Cap
LossP/E TTM
More Details of Cidara Therapeutics Inc Company
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Cidara Therapeutics Inc Info
Ticker SymbolCDTX
Company nameCidara Therapeutics Inc
IPO dateApr 15, 2015
CEOStein (Jeffrey L)
Number of employees38
Security typeOrdinary Share
Fiscal year-endApr 15
Address6310 Nancy Ridge Dr Ste 101
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121-3209
Phone18587526170
Websitehttps://www.cidara.com/
Ticker SymbolCDTX
IPO dateApr 15, 2015
CEOStein (Jeffrey L)
Company Executives of Cidara Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brian Ritchie
Mr. Brian Ritchie
Investor Relations
Investor Relations
--
--
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
--
--
Mr. Shane Ward
Mr. Shane Ward
Chief Operating Officer, Chief Legal Officer, Company Secretary
Chief Operating Officer, Chief Legal Officer, Company Secretary
--
--
Dr. Josh Resnick, M.D., J.D.
Dr. Josh Resnick, M.D., J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
10.70%
Bain Capital Life Sciences Investors, LLC
9.61%
Point72 Asset Management, L.P.
5.02%
Vivo Capital, LLC
4.17%
The Vanguard Group, Inc.
3.90%
Other
66.60%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
10.70%
Bain Capital Life Sciences Investors, LLC
9.61%
Point72 Asset Management, L.P.
5.02%
Vivo Capital, LLC
4.17%
The Vanguard Group, Inc.
3.90%
Other
66.60%
Shareholder Types
Shareholders
Proportion
Hedge Fund
36.36%
Investment Advisor
26.67%
Venture Capital
19.42%
Investment Advisor/Hedge Fund
17.45%
Research Firm
3.58%
Individual Investor
0.60%
Private Equity
0.38%
Bank and Trust
0.14%
Pension Fund
0.13%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
275
32.66M
93.43%
-89.39K
2025Q3
272
32.69M
113.07%
+5.45M
2025Q2
192
26.01M
58.78%
+14.85M
2025Q1
116
10.29M
62.84%
+2.62M
2024Q4
117
7.61M
59.71%
+797.06K
2024Q3
101
4.05M
48.02%
+1.19M
2024Q2
100
1.46M
32.79%
+316.14K
2024Q1
99
1.10M
625.81%
-324.56K
2023Q4
101
1.37M
36.42%
-113.04K
2023Q3
108
1.48M
40.49%
-50.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
3.37M
13.27%
--
--
Aug 07, 2025
Bain Capital Life Sciences Investors, LLC
2.50M
9.86%
+1.80M
+255.68%
Jun 30, 2025
Point72 Asset Management, L.P.
1.53M
6.03%
+528.52K
+52.88%
Jun 30, 2025
Vivo Capital, LLC
1.31M
5.17%
+627.15K
+91.65%
Jun 30, 2025
The Vanguard Group, Inc.
966.71K
3.81%
+457.13K
+89.71%
Jun 30, 2025
BVF Partners L.P.
786.39K
3.1%
-138.25K
-14.95%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.02M
4.03%
+974.57K
+2030.95%
Jun 30, 2025
Darwin Global Management Ltd
768.42K
3.03%
+768.42K
--
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.13M
4.45%
+1.13M
--
Jul 23, 2025
VR Adviser, LLC
639.09K
2.52%
-412.43K
-39.22%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Health Care ETF
5.81%
Invesco Dorsey Wright Healthcare Momentum ETF
3.83%
Invesco Dorsey Wright SmallCap Momentum ETF
1.58%
First Trust Small Cap Growth AlphaDEX Fund
1.33%
State Street SPDR S&P Biotech ETF
0.84%
Direxion Daily S&P Biotech Bull 3X Shares
0.52%
Even Herd Long Short ETF
0.42%
iShares Micro-Cap ETF
0.32%
VictoryShares US Small Mid Cap Value Momentum ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.22%
View more
Simplify Health Care ETF
Proportion5.81%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.83%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion1.58%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.33%
State Street SPDR S&P Biotech ETF
Proportion0.84%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.52%
Even Herd Long Short ETF
Proportion0.42%
iShares Micro-Cap ETF
Proportion0.32%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.28%
First Trust Small Cap Core Alphadex Fund
Proportion0.22%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 22, 2024
Merger
20→1
Apr 22, 2024
Merger
20→1
Apr 22, 2024
Merger
20→1
Apr 22, 2024
Merger
20→1
Date
Type
Ratio
Apr 22, 2024
Merger
20→1
Apr 22, 2024
Merger
20→1
Apr 22, 2024
Merger
20→1
Apr 22, 2024
Merger
20→1
FAQs
Who are the top five shareholders of Cidara Therapeutics Inc?
The top five shareholders of Cidara Therapeutics Inc are:
RA Capital Management, LP holds 3.37M shares, accounting for 13.27% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 2.50M shares, accounting for 9.86% of the total shares.
Point72 Asset Management, L.P. holds 1.53M shares, accounting for 6.03% of the total shares.
Vivo Capital, LLC holds 1.31M shares, accounting for 5.17% of the total shares.
The Vanguard Group, Inc. holds 966.71K shares, accounting for 3.81% of the total shares.
RA Capital Management, LP holds 3.37M shares, accounting for 13.27% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 2.50M shares, accounting for 9.86% of the total shares.
Point72 Asset Management, L.P. holds 1.53M shares, accounting for 6.03% of the total shares.
Vivo Capital, LLC holds 1.31M shares, accounting for 5.17% of the total shares.
The Vanguard Group, Inc. holds 966.71K shares, accounting for 3.81% of the total shares.
What are the top three shareholder types of Cidara Therapeutics Inc?
The top three shareholder types of Cidara Therapeutics Inc are:
RA Capital Management, LP
Bain Capital Life Sciences Investors, LLC
Point72 Asset Management, L.P.
RA Capital Management, LP
Bain Capital Life Sciences Investors, LLC
Point72 Asset Management, L.P.
How many institutions hold shares of Cidara Therapeutics Inc (CDTX)?
As of 2025Q4, 275 institutions hold shares of Cidara Therapeutics Inc, with a combined market value of approximately 32.66M, accounting for 93.43% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -19.64%.
What is the biggest source of revenue for Cidara Therapeutics Inc?
In --, the -- business generated the highest revenue for Cidara Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
